JP7090034B2 - 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子 - Google Patents

化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子 Download PDF

Info

Publication number
JP7090034B2
JP7090034B2 JP2018561060A JP2018561060A JP7090034B2 JP 7090034 B2 JP7090034 B2 JP 7090034B2 JP 2018561060 A JP2018561060 A JP 2018561060A JP 2018561060 A JP2018561060 A JP 2018561060A JP 7090034 B2 JP7090034 B2 JP 7090034B2
Authority
JP
Japan
Prior art keywords
ncp
lipid
cancer
particles
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018561060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523757A5 (enExample
JP2019523757A (ja
Inventor
リン ウェンビン
デュアン シャオピン
チャン クリスティーナ
ハン ウェンボ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2019523757A publication Critical patent/JP2019523757A/ja
Publication of JP2019523757A5 publication Critical patent/JP2019523757A5/ja
Priority to JP2022032275A priority Critical patent/JP2022078190A/ja
Application granted granted Critical
Publication of JP7090034B2 publication Critical patent/JP7090034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018561060A 2016-05-20 2017-05-22 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子 Active JP7090034B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022032275A JP2022078190A (ja) 2016-05-20 2022-03-03 治療薬を送達するためのナノスケール粒子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339594P 2016-05-20 2016-05-20
US62/339,594 2016-05-20
PCT/US2017/033822 WO2017201528A1 (en) 2016-05-20 2017-05-22 Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022032275A Division JP2022078190A (ja) 2016-05-20 2022-03-03 治療薬を送達するためのナノスケール粒子

Publications (3)

Publication Number Publication Date
JP2019523757A JP2019523757A (ja) 2019-08-29
JP2019523757A5 JP2019523757A5 (enExample) 2020-06-25
JP7090034B2 true JP7090034B2 (ja) 2022-06-23

Family

ID=60326621

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561060A Active JP7090034B2 (ja) 2016-05-20 2017-05-22 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
JP2022032275A Pending JP2022078190A (ja) 2016-05-20 2022-03-03 治療薬を送達するためのナノスケール粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022032275A Pending JP2022078190A (ja) 2016-05-20 2022-03-03 治療薬を送達するためのナノスケール粒子

Country Status (5)

Country Link
US (1) US11246877B2 (enExample)
EP (1) EP3439666A4 (enExample)
JP (2) JP7090034B2 (enExample)
CN (1) CN109310702A (enExample)
WO (1) WO2017201528A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11826426B2 (en) 2017-08-02 2023-11-28 The University Of Chicago Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
US11872311B2 (en) 2011-07-08 2024-01-16 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
WO2018213631A1 (en) * 2017-05-18 2018-11-22 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
US11433143B2 (en) 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
WO2019109126A1 (en) * 2017-12-06 2019-06-13 Newsouth Innovations Pty Limited Liposomal system for drug delivery
JP7474702B2 (ja) 2018-03-28 2024-04-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
CN112512507A (zh) * 2018-04-19 2021-03-16 得克萨斯州大学系统董事会 使用外排体对肿瘤抑制因子的治疗性调节
CN108619511B (zh) * 2018-04-20 2020-12-15 山东大学 一种基于阿糖胞苷小分子前药的金属有机框架载药系统的制备方法和应用
CN108840896A (zh) * 2018-04-23 2018-11-20 上海大学 刺激响应型双亲大分子及其制备方法
CN108774264A (zh) * 2018-05-18 2018-11-09 东北林业大学 卵磷脂类似物、制备方法及用途
CN108794532A (zh) * 2018-05-18 2018-11-13 东北林业大学 脑磷脂类似物、制备方法及用途
CN110872324B (zh) * 2018-08-29 2021-09-14 中国科学院上海药物研究所 奥沙利铂偶联前药、其制备方法及用途
IL282213B2 (en) 2018-10-16 2025-07-01 Silicycle Inc A tunable process for the preparation and use of silica capsules/spheres
CN109336857A (zh) * 2018-11-13 2019-02-15 南方医科大学 一种含取代联苯的黄酮及其应用
US12358941B2 (en) 2019-03-07 2025-07-15 Virginia Commonwealth University Lipidic analogs of anti-cancer stem cell agent
CN111840228A (zh) * 2019-04-09 2020-10-30 中国科学院上海药物研究所 肿瘤免疫脂质体，其制备方法和用途
WO2020217472A1 (ja) * 2019-04-26 2020-10-29 株式会社Jimro 治療抵抗性がんの予防又は治療用の医薬組成物
EP3747467A3 (en) * 2019-06-03 2021-03-03 Nanobacterie A cryosystem comprising nanoparticles for treating a body part of an individual by cryotherapy
CN110201162B (zh) * 2019-06-14 2021-09-07 中山大学附属第八医院（深圳福田） 光治疗剂在打破肿瘤免疫抑制微环境中的应用
CN110507613A (zh) * 2019-07-29 2019-11-29 苏州大学 一种脂质体制剂及其制备方法与应用
CN114401736A (zh) * 2019-08-13 2022-04-26 佩蒂诺沃生物制药公司 用于治疗伴随癌症治疗发生的化学疗法诱导的周围神经病变的palm
BR112022004482A2 (pt) * 2019-09-12 2022-05-31 Cellectar Biosciences Inc Conjugados de éter fosfolipídico como veículos de fármacos direcionados ao câncer
CN110862546B (zh) * 2019-10-12 2021-07-09 厦门大学 一种甲氨蝶呤金属配位聚合物及其制备方法和应用
AU2020367786A1 (en) * 2019-10-14 2022-05-26 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
CN111214646B (zh) * 2019-12-30 2023-08-01 中山大学·深圳 Pd-l1/ctla-4在制备免疫抑制剂中的应用
CN111423497B (zh) * 2020-03-16 2021-12-24 山东大学 拮抗肽、其共聚物及纳米组装体、及其制备方法和应用
WO2021237209A1 (en) * 2020-05-22 2021-11-25 The University Of Chicago Metal-organic frameworks deliver small molecules and biomacromolecules for cancer immunotherapy
WO2022009788A1 (ja) * 2020-07-08 2022-01-13 コニカミノルタ株式会社 細胞の殺傷方法、シンチレーター粒子
CN114053223B (zh) * 2020-08-07 2023-04-07 中国科学院上海药物研究所 复合脂质体、其制备方法及用途
EP4188361A4 (en) * 2020-08-21 2025-01-22 The University of Chicago NANOPARTICLES WITH MULTIPLE CLEAVABLE PRODRUGS FOR CANCER THERAPY
US20230312744A1 (en) * 2020-09-02 2023-10-05 The University Of Tokyo Modulatory Substance of Tumor Immune Microenvironment, and Preventive, Diagnostic and/or Therapeutic Utilization of the Same
KR20230066582A (ko) * 2020-09-10 2023-05-16 남미 테라퓨틱스, 인크. 암의 치료에 유용한 pd-1 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
CN112353948B (zh) * 2020-10-21 2021-08-27 四川大学 响应酸性微环境实现粒径减小和表面电荷翻转的载药胶束及其制备方法
CN112321615B (zh) * 2020-10-30 2021-11-09 华中科技大学 一种基于喜树碱的二聚体化合物、其制备和应用
WO2022088679A1 (zh) * 2020-10-30 2022-05-05 华中科技大学 一种清除肿瘤干细胞的方法、抗癌药物、载药系统及其应用
JP2022104889A (ja) * 2020-12-28 2022-07-12 財團法人工業技術研究院 免疫刺激性リポプレックス、免疫刺激性リポプレックスを含む医薬組成物、およびその用途
CN115154462B (zh) * 2021-04-01 2024-04-09 首都医科大学附属北京朝阳医院 双氢青蒿素在预防和/或治疗多发性骨髓瘤中的应用
CN113230401A (zh) * 2021-04-26 2021-08-10 上海大学 一种核壳上转换MOFs光敏复合材料、制备方法及其应用
CN113384696A (zh) * 2021-06-07 2021-09-14 深圳大学 一种纳米光敏剂、制备方法及其应用
CN113975392A (zh) * 2021-10-29 2022-01-28 成都大学 一种光动力介导抗肿瘤免疫应答的二氢青蒿素纳米制剂及其制备方法与应用
CN114224823B (zh) * 2021-11-02 2023-12-05 南京医科大学 一种集化疗/光动力治疗/化学动力治疗“三位一体”的脑胶质瘤递药系统及其制备方法
CN114601972B (zh) * 2022-02-08 2022-10-18 山东科技大学 以镁/镁合金/锌/锌合金为基体的光热、光动力、金属离子协同抗菌材料及其制备方法
CN114588268B (zh) * 2022-03-25 2023-05-26 清华大学 提高激活sting通路和抗肿瘤t细胞应答的方法
CN114949208B (zh) * 2022-05-06 2023-07-04 温州医科大学 纳米光动力材料及其脉络膜新生血管的治疗的应用
CN114983943A (zh) * 2022-06-16 2022-09-02 苏州卫生职业技术学院 一种青蒿琥酯纳米靶向制剂及其制备方法与应用
CN115165828B (zh) * 2022-06-30 2025-01-28 曲阜师范大学 一种基于Zn-MOF原位显色的青蒿素比率荧光分析方法
KR20240107310A (ko) * 2022-12-29 2024-07-09 가톨릭대학교 산학협력단 면역관문 억제제의 항암 효과 증진용 약학적 조성물
IT202300015396A1 (it) * 2023-07-21 2025-01-21 Torino Politecnico Nanoparticelle rivestite e loro uso per il trasporto di agenti terapeutici e diagnostici
CN119431497B (zh) * 2023-07-31 2025-10-21 北京大学 靶向pd-l1蛋白的光敏剂嵌合体及其制备方法和应用
WO2025077898A1 (en) * 2023-10-13 2025-04-17 The Chinese University Of Hong Kong A therapeutic nucleic acid-encased nanoworm for gene delivery and endosomal escape
CN117442601B (zh) * 2023-10-31 2024-05-28 上海市东方医院（同济大学附属东方医院） 一种磷酸酶抑制剂类似物BX-金属NPs及其制备方法和应用
CN118576709B (zh) * 2024-05-23 2025-10-17 大连理工大学 一种光敏性载体及其制备方法与应用
CN120114415B (zh) * 2025-05-15 2025-08-29 浙江大学 一种具有腹腔靶向性的氯膦酸盐脂质纳米颗粒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069926A1 (en) 2013-11-06 2015-05-14 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
WO2016061256A1 (en) 2014-10-14 2016-04-21 The University Of Chicago Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61351A (en) 1980-10-27 1983-12-30 Yeda Res & Dev Organometallic polymers,their preparation and compositions of co-ordination compounds containing them
US5147806A (en) 1988-04-29 1992-09-15 Igen, Inc. Method and apparatus for conducting electrochemiluminescence measurements
US5213788A (en) 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
CA2086527A1 (en) 1990-07-26 1992-01-27 Samuel J. Tremont Polymeric drug delivery system
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5591730A (en) 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US5641623A (en) 1995-01-04 1997-06-24 Martin; Mark T. Electrochemiluminescence assay
US20010003647A1 (en) 1995-06-07 2001-06-14 Ji Sun Coreatant-including electrochemiluminescent compounds, methods, systems and kits utilizing same
US6022737A (en) 1995-11-02 2000-02-08 Amgen Inc. Formulations for non-viral in vivo transfection in the lungs
US5648508A (en) 1995-11-22 1997-07-15 Nalco Chemical Company Crystalline metal-organic microporous materials
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ATE236188T1 (de) 1997-01-24 2003-04-15 Conpharma As Gemcitabin-derivate
US6180082B1 (en) 1997-11-24 2001-01-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method to enhance tissue accumulation of radiolabeled compounds
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US6818227B1 (en) 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
EP1161226B1 (en) * 1999-02-18 2004-05-26 SuperGen, Inc. Phosphocholine linked prodrug derivatives
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US6602932B2 (en) 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
CA2405360A1 (en) 2000-04-07 2001-10-18 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
US6548264B1 (en) 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
ES2269761T3 (es) 2001-04-30 2007-04-01 The Regents Of The University Of Michigan Estructuras organometalicas isorreticulares, procedimiento para su formacion, y diseño sistematico del calibre de poros y funcionalidad de los mismos, con aplicacion para el almacenamiento de gases.
AU2003226082A1 (en) 2002-03-25 2003-11-11 The General Hospital Corporation Methods of adjuvant photodynamic therapy to enhance radiation sensitization
CA2499977A1 (en) 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Edible solid composition and dosage form
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
KR100401335B1 (en) 2003-03-08 2003-10-10 Mijitech Co Ltd Metal nanoparticle surface-coated with silicon oxides and preparation thereof
US6878838B2 (en) 2003-03-24 2005-04-12 The University Of North Carolina At Chapel Hill Chiral porous metal phosphonates for heterogeneous asymmetric catalysis
WO2004084871A1 (en) 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targenting drug delivery and sustained drug release
WO2004089345A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals Inc. Bone targeting of biodegradable drug-containing nanoparticles
KR101278432B1 (ko) 2003-05-09 2013-07-04 더 리젠츠 오브 더 유니버시티 오브 미시간 결정들에서 우수한 수준의 표면적과 다공성의 성취를 위한 방법의 이행
AU2004261243A1 (en) 2003-07-31 2005-02-10 3M Innovative Properties Company Bioactive compositions comprising triazines
US20050227929A1 (en) 2003-11-13 2005-10-13 Masferrer Jaime L Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
US20050147963A1 (en) 2003-12-29 2005-07-07 Intel Corporation Composite organic-inorganic nanoparticles and methods for use thereof
JP4487032B2 (ja) 2004-03-29 2010-06-23 独立行政法人放射線医学総合研究所 ヒール効果補正フィルタ、ｘ線照射装置、ｘ線ｃｔ装置及びｘ線ｃｔ撮像方法
US20070259966A1 (en) 2004-04-22 2007-11-08 Allos Therapeutics, Inc. Coadministration of Radiation, Efaproxiral Sodium, and Supplemental Oxygen for the Treatment of Cancer
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
FR2874016B1 (fr) 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US20070218049A1 (en) 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
JP4992091B2 (ja) 2005-02-17 2012-08-08 ハダシット メディカル リサーチ サービシーズ アンド デベロップメント リミテッド 子宮内膜症を治療するためのビスホスホネート
CN1305937C (zh) 2005-02-25 2007-03-21 复旦大学 一种金属配位聚合物纳米结构材料的制备方法
EP1865928A1 (en) 2005-03-17 2007-12-19 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
PE20070360A1 (es) 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20080095699A1 (en) 2006-10-20 2008-04-24 Shiying Zheng Imaging contrast agents using nanoparticles
US7263170B2 (en) 2005-09-30 2007-08-28 Pellegrino Anthony J Radiation therapy system featuring rotatable filter assembly
US20070088161A1 (en) 2005-10-19 2007-04-19 Stockel Richard F Novel chelated bisphosphonates for use as pharmaceutical agents
US20090242856A1 (en) 2006-02-09 2009-10-01 Simon Fraser University Birefringent metal-containing coordination polymers
US20100189222A1 (en) 2006-02-16 2010-07-29 Steller Micro Devices Panoramic irradiation system using flat panel x-ray sources
KR100943923B1 (ko) 2006-03-17 2010-02-24 홍순해 킬레이팅 유기 고분자와 생물학적 금속으로 이루어진 나노입자, 그리고 ｅｐｒ 효과를 이용한 새로운 광범위 무독성항암제 및 그 제조 방법
US20090317335A1 (en) 2006-04-20 2009-12-24 Wenbin Lin Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
WO2008016172A1 (fr) 2006-08-04 2008-02-07 Kurume University Inhibiteur de métastase
US7985868B1 (en) 2006-11-01 2011-07-26 Sandia Corporation Hybrid metal organic scintillator materials system and particle detector
US20080124281A1 (en) 2006-11-29 2008-05-29 Board Of Regents, The University Of Texas System Nanotubular probes as ultrasensitive mr contrast agent
JPWO2008102632A1 (ja) 2007-02-21 2010-05-27 コニカミノルタエムジー株式会社 Ｘ線バンドパスフィルタ、ｘ線照射システム及びｘ線撮影システム
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8691748B2 (en) 2007-09-25 2014-04-08 The Regents Of The University Of California Edible and biocompatible metal-organic frameworks
FR2921838A1 (fr) 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
WO2009139939A2 (en) 2008-02-22 2009-11-19 The University Of North Carolina At Chapel Hill Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
WO2009114476A1 (en) 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising survivin sirna and methods of use thereof
GB0807862D0 (en) 2008-04-29 2008-06-04 Uni I Oslo Compounds
WO2010096464A1 (en) 2009-02-18 2010-08-26 Boyes Stephen G Gold/lanthanide nanoparticle conjugates and uses thereof
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
US9302003B2 (en) 2009-04-24 2016-04-05 Socpra—Sciences Santé´Et Humaines Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
WO2010140986A1 (en) 2009-06-05 2010-12-09 Nanyang Technological University Targetted drug delivery to the bone
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
WO2011049743A1 (en) 2009-10-06 2011-04-28 Stellarray, Inc. Self contained irradiation system using flat panel x-ray sources
EP2488206B1 (en) 2009-10-16 2018-03-21 University Health Network (UHN) Porphyrin nanovesicles
AU2010322516A1 (en) 2009-11-20 2012-05-17 Clavis Pharma Asa Parenteral formulations of gemcitabine derivatives
GB201013307D0 (en) 2010-08-09 2010-09-22 Univ St Andrews Anti-microbial metal organic framework
IT1401882B1 (it) 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
WO2012138419A1 (en) 2011-04-04 2012-10-11 Georgia Tech Research Corporation Mof nanocrystals
NO2694640T3 (enExample) 2011-04-15 2018-03-17
US20120301537A1 (en) 2011-05-23 2012-11-29 Delta-Fly Pharma, Inc. LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
JP6076968B2 (ja) 2011-06-06 2017-02-08 ユニバーシティ・ヘルス・ネットワーク ポルフィリン−リン脂質コンジュゲートを合成する方法
EP2721032A4 (en) 2011-06-16 2014-11-05 Univ South Florida POLYHEDRIC CAGE WITH METAL OPORPHYRENE EQUIPMENT, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
JP6049712B2 (ja) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
WO2013012628A2 (en) 2011-07-15 2013-01-24 The University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
CN102432654A (zh) 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
WO2013068965A2 (en) 2011-11-11 2013-05-16 Koninklijke Philips Electronics N.V. Lighting apparatus and manufacturing method for manufacturing the lighting apparatus
MX362089B (es) 2011-12-16 2019-01-07 Nanobiotix Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.
WO2013188763A1 (en) 2012-06-15 2013-12-19 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
WO2014107873A1 (zh) 2013-01-11 2014-07-17 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的试剂、其用途及方法
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
US10647733B2 (en) 2014-03-28 2020-05-12 The University Of Chicago Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations
WO2015149068A1 (en) 2014-03-28 2015-10-01 The University Of Chicago Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
US20180214563A1 (en) * 2015-07-31 2018-08-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immunostimulatory nanocarrier
US10953393B2 (en) 2015-10-12 2021-03-23 The University Of Chicago Stabilization of active metal catalysts at metal-organic framework nodes for highly efficient organic transformations
CN105457038A (zh) 2015-11-09 2016-04-06 东南大学 一种速释型药物磷脂化合物及其药物组合物
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069926A1 (en) 2013-11-06 2015-05-14 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
WO2016061256A1 (en) 2014-10-14 2016-04-21 The University Of Chicago Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry，2012年，Vol.23, No.6，p.1091-1104
Biomacromolecules，2015年，Vol.16, No.7，p.1886-1914
Eur.J.Biomed.Res.，2016年01月31日，Vol.2, No.1，p.8-15
Journal of Controlled Release，2015年，Vol.208，p.25-41
Nature Com.，2014年，Vol.5, Article number: 4182，p.1-11
Theranotics，2016年04月28日，Vol.6, No.7，p.1065-1074

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872311B2 (en) 2011-07-08 2024-01-16 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US11826426B2 (en) 2017-08-02 2023-11-28 The University Of Chicago Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof

Also Published As

Publication number Publication date
CN109310702A (zh) 2019-02-05
JP2022078190A (ja) 2022-05-24
US11246877B2 (en) 2022-02-15
EP3439666A4 (en) 2019-12-11
EP3439666A1 (en) 2019-02-13
WO2017201528A1 (en) 2017-11-23
US20190269706A1 (en) 2019-09-05
JP2019523757A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
JP7090034B2 (ja) 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
US10780045B2 (en) Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
US10806694B2 (en) Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
JP6590802B2 (ja) 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体
CN111194232B (zh) 纳米级金属有机层和金属有机纳米片
US20230293698A1 (en) Metal-organic frameworks deliver small molecules and biomacromolecules for cancer immunotherapy
US20240042045A1 (en) Nanoparticles containing multiple cleavable produgs for cancer therapy
WO2013009701A9 (en) Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US20170332910A1 (en) Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof
JP2021535258A (ja) シアニンベースをベースとするテロデンドリマー及び癌治療のための使用
Chenab et al. Intertumoral and intratumoral barriers as approaches for drug delivery and theranostics to solid tumors using stimuli-responsive materials
CN114746124A (zh) 包含活性剂沉淀物的递送系统复合物和使用方法
Valcourt Treating triple-negative breast cancer through nanoparticle-mediated photothermal therapy and gene regulation
Yen Terpolymer-Lipid Hybrid MnO2 Nanoparticles as Theranostic Agents for Improving Magnetic Resonance Imaging of Solid Tumors and Image-Guided Radiation Therapy of Glioblastoma Multiforme
Qu et al. Drug-drug conjugates self-assembled nanomedicines triggered photo−/immuno-therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200515

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220303

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220303

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220408

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220613

R150 Certificate of patent or registration of utility model

Ref document number: 7090034

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250